Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSS06
- Development stage
- Phase 3
- Lead developer
- 3SBio
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
SSS06 is a long-acting, PEGylated recombinant human thrombopoietin (rhTPO) developed by 3S Bio. It is designed to address the limitations of first-generation rhTPO, such as the need for frequent administration, by utilizing PEGylation technology to extend the protein's circulating half-life. SSS06 acts as an agonist of the thrombopoietin receptor (MPL), mimicking the action of endogenous thrombopoietin to stimulate the growth and maturation of megakaryocytes, thereby increasing platelet production. The drug is primarily being developed for the treatment of chemotherapy-induced thrombocytopenia (CIT), a common complication of cancer treatment that can lead to dose reductions or delays in chemotherapy. By maintaining higher platelet counts, SSS06 aims to improve the safety and efficacy of myelosuppressive oncological regimens.
- Brand names
- NuPIAO
- Other names
- PEG-rhTPOPEGylated recombinant human thrombopoietin
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on SSS06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSS06.